Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes

This publication has 36 references indexed in Scilit:

• Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
  New England Journal of Medicine, 2006
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
  Diabetes Care, 2006
• Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
  Diabetes Care, 2004
• Sulfonylurea Inadequacy
  Diabetes Care, 2002
• Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)
  JAMA, 1999
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  The Lancet, 1998
• Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study
  Diabetic Medicine, 1998
• U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group
  Diabetes, 1995
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study
  Diabetes Research and Clinical Practice, 1995
• The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
  New England Journal of Medicine, 1993